Have a personal or library account? Click to login
Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging Cover

Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging

Open Access
|Mar 2009

Abstract

[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu] ATSM) was prepared using in house-made diacetyl-bis(N4-methylthiosemicarbazone) (ATSM) ligand and [61Cu]CuCl2 produced via the natZn(p, x)61Cu (180 μA proton irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method. [61Cu]ATSM radiochemical purity was >98 %, as shown by HPLC and RTLC methods. [61Cu]ATSM was administered into normal and tumor bearing rodents for up to 210 minutes, followed by biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation was observed either by animal sacrification or imaging. [61Cu]ATSM is a positron emission tomography (PET) radiotracer for tumor hypoxia imaging.

DOI: https://doi.org/10.2478/v10007-009-0008-9 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 45 - 55
Published on: Mar 20, 2009
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2009 Amir Jalilian, Nima Rostampour, Pejman Rowshanfarzad, Kamaleddin Shafaii, Mohsen Kamali-Dehghan, Mehdi Akhlaghi, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Volume 59 (2009): Issue 1 (March 2009)